Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Rhinosinusitis Without Nasal Polyps: full-pipeline trial registry
2 of 3 indexed Chronic Rhinosinusitis Without Nasal Polyps trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Chronic Rhinosinusitis Without Nasal Polyps: 3 US clinical trials tracked, 2 recruiting.
Chronic Rhinosinusitis Without Nasal Polyps is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Optinose US, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-rhinosinusitis-without-nasal-polyps
OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Chronic Rhinosinusitis Without Nasal Polyps lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Rhinosinusitis Without Nasal Polyps on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Rhinosinusitis Without Nasal Polyps is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
3D Printing to Improve Nasal Irrigation Outcome
Ohio State University
NCT06118554
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Optinose US
NCT06850805
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
Sanofi
NCT06691113
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Rhinosinusitis Without Nasal Polyps records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Rhinosinusitis Without Nasal Polyps trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Rhinosinusitis Without Nasal Polyps page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Chronic Rhinosinusitis Without Nasal Polyps trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Optinose US sponsors the most Chronic Rhinosinusitis Without Nasal Polyps trials on record, review their full trial history before evaluating a specific study. See Optinose US's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Rhinosinusitis Without Nasal Polyps condition card totals 3 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.